ADVERTISEMENT
Log in here to read the desired article.
ADVERTISEMENT
This author has not written his bio yet.
But we are proud to say that Thomas Gabrielczyk contributed 2188 entries already.
Copenhagen-based SNIPR BIOME Aps raised €43m in a series A financing led by seed investor Lundbeckfonden Emerge (Copenhagen) and LSP and co-financed by North-East Family Office (Copenhagen) and Wellington Partners (Munich).
Researchers at Janssen Pharmaceutical Companies of Johnson & Johnson in Leiden have developed a small molecule antibody mimic, that prevents entry of multiple influenza virus serotypes.
Seventure Partners has announced the first close of its second microbiome fund designed to put €200m in 20 companies developing microbiome-based health solutions.
Swiss immunology and immuno-oncology specialist Numab Innovation AG has licenced its tri-specific antibody ND016 to Boston-based Intarcia Therapeutics Inc.
Biogen has strengthened its portfolio with Nightstar Therapeutics, a British gene therapy specialist for rare inherited eye disorders.
The EMA‘s human medicines committee (CHMP) has recommended eight medicines for approval in its last meeting in London, two thereof orphan medicines. Three got conditional marketing authorisation.
High-potency drugs present numerous opportunities for improved drug selectivity, efficacy and safety profiles, and represent a growing area of global development focus, for applications such as oncology and hormone-based treatments. Although this class of molecules offers numerous benefits to patients, they require particular care and attention in ensuring the safety for those involved in their manufacture and handling.
French Genfit SA has registered at SEC for an Nasdaq IPO of ADS in conjunction with private placements in Europe and the US.
Six times as many decision-makers attended the 3rd European Chemistry Partnering today- compared to the initial event two years ago: with participants from Brazil, Morocco and Australia, all six continents were represented for the first time. More than 2,000 partnering meetings formed the basis of interdisciplinary exchanges regarding innovation. In addition, there were countless discussions in the exhibition area, at the speaker corners and during the many networking opportunities.
Researchers from the UK and the US have prevented tendon injury and degeneration by simply blocking a key signalling pathway in inflammation.